At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 148 enrolled

Drug / intervention

Truvadadrug

Likely dose

Truvada 200 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02213328

NCT02213328Phase 2Completed

Compare CT.gov

CHAMPS: Choices For Adolescent Prevention Methods For South Africa. Pilot Study B: 'PlusPills'

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Aug 11, 2014·Updated Jul 3, 2023

In Brief

A Phase 2 clinical trial evaluating Truvada for HIV Infections. Completed, enrolled 148 participants across 2 sites.

Detailed Summary

Truvada (emtricitabine/tenofovir disoproxil fumarate, or FTC/TDF) is a type of antiretroviral (ARV) medicine that is commonly used to treat HIV. Truvada is also used as pre-exposure prophylaxis (PrEP) to prevent HIV infection in HIV-negative adults. The purpose of this study is to evaluate the acceptability, safety, and use of daily Truvada PrEP as part of a comprehensive HIV prevention package in healthy, HIV-uninfected adolescents 15 to 19 years of age.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsHIV Infections

CountriesSouth Africa

Collaborators--

Timeline

Phase 2CompletedFinished

201520162017201820192020202120222023202420252026

First PostedAug 2014

Enrollment StartApr 2015

Primary CompletionMar 2017

TodayJul 2026

First PostedAug 11, 2014

Enrollment StartApr 1, 2015

Primary CompletionMar 6, 2017

TodayJul 2, 2026

Enrollment to primary: 1.9 yearsPosted 11.9 years ago

Interventions

Truvadadrug

Fixed-dose combination tablet containing 200 mg of FTC plus 300 mg of TDF, taken once daily by mouth.